Funding Affordable Healthcare in India
Health access attracts more patient capital in India than almost any other theme. It's also where the qualification test bites hardest, because a lot of Indian healthcare is already commercially fundable, and patient money has no business going there.
Summary
- Health access attracts more patient capital in India than almost any other theme, but urban hospitals, premium diagnostics and digital health for the connected are already commercially funded.
- Funders pay for outcomes, not outputs: first-time access, what the patient would otherwise have done, and what the episode cost the household.
- Healthcare assets are heavy and slow to pay back. Split the requirement: equipment is a debt question, proving a model is a grant question, expansion is an equity question.
If you run a healthcare business in India and you've never had a conversation with a foundation or a development institution, you're in a large group. It's an odd one to be in, because health access attracts more patient capital in this country than almost any other theme.
Dedicated blended finance facilities have been built around Indian healthcare. Global health foundations have been active here for decades. Development institutions fund hospitals, diagnostics and health financing. Outcome-based structures have been piloted in maternal and newborn health. The money is not theoretical and it is not small.
And yet the sector is also where I see the qualification test bite hardest, for a reason that's worth understanding before you spend a quarter on it: a great deal of Indian healthcare is already commercially fundable, and patient capital has no business going there.
The line that actually matters
Private and venture capital have been enthusiastic about Indian healthcare for years. Urban multi-specialty hospitals. Single-specialty chains in metros. Premium diagnostics. Health insurance. Digital health platforms serving people with smartphones and disposable income.
None of that needs concessional capital, and a foundation asked to subsidise it would decline on principle rather than on merit.
The gap sits somewhere else. care in towns where the nearest decent hospital is three hours away. Diagnostics in districts a national chain has decided aren't worth the capex. Primary care for households paying out of pocket, where the alternative isn't a cheaper provider: it's not going. Devices designed down to a price point rather than up to a specification. Supply chains reaching pharmacies that no distributor services properly.
The distinguishing feature isn't that the business is in healthcare. It's that the economics don't work well enough for commercial capital to have shown up, and yet the need is obvious. That's the gap patient money exists to close.
Which means the first question for any healthcare founder considering this lane isn't "are we impact." It's "would a PE fund have written this cheque anyway?" If the honest answer is yes, the commercial lane is faster and you should take it.
What funders are actually measuring in health
Health has the advantage of being one of the more mature measurement areas: the frameworks are well developed and the expectations are clear. It also has a trap in it that catches a lot of founders.
The trap is outputs versus outcomes.
Tests conducted is an output. Patients seen is an output. Beds added is an output. Every founder has these numbers, they're easy to report, and they impress nobody who does this for a living.
What gets funded is the layer underneath. How many of those patients had never had access to this kind of care before. What they were doing instead: travelling, delaying, self-medicating, going without. What the test actually led to: was a diagnosis made, was treatment started, did the person come back. What the episode cost the household compared to the alternative, because out-of-pocket health spending is one of the more reliable routes into poverty in India, and reducing it is a legible outcome to every funder in this space.
The good news is that a functioning healthcare business generates almost all of this as a by-product. Patient records hold geography. Billing holds what people paid. Repeat visits are in the system. Referral patterns show what happened next. It's rarely assembled, but it's rarely missing.
The harder one is the counterfactual: what the patient would have done if you weren't there. Nobody has that in their records. It comes from asking, and it's worth building into intake early, because it can't be reconstructed later.
Where each sub-segment tends to land
A rough map, and the honest version rather than the encouraging one.
- Diagnostics in tier-2 and beyond: often the cleanest case in the sector. First-time access is easy to evidence, geography is in the data, and the capex-heavy model genuinely struggles to attract commercial funding outside metros.
- Secondary care hospitals in smaller towns: strong on need, and the additionality argument is usually straightforward. The complication is that these are capital-intensive and the instrument question matters more than the impact question.
- Primary care and clinic chains: depends entirely on who walks in. Serving households paying out of pocket for care they'd otherwise skip is a real case. Serving salaried urban customers is a commercial business with good margins.
- Affordable medical devices: frequently compelling, particularly where the product is designed to a price point that opens access. Often a technical-assistance and grant conversation at the early stage rather than an equity one.
- Digital health: the hardest to qualify, and founders are often surprised by that. Much of it serves people who already had access and are now getting it more conveniently, which is a genuine product improvement and not an access story. It qualifies when it reaches people who were outside the system.
- Health financing and insurance for low-income households: sits across health and financial inclusion, and often has the widest funder shelf of anything on this list.
The instrument question people skip
This is where I'd spend the most time if you take nothing else from this piece.
Healthcare in underserved geographies is capital-intensive in a very specific way. Equipment. Fit-outs. Beds. Long periods on assets that take years to reach .
Founders routinely fund that with equity, because equity is the instrument they were shown. It is close to the most expensive way to buy a scanner. What that requirement actually calls for is debt with a tenor long enough to match the asset life, and the reason it doesn't get funded commercially is usually tenor rather than risk. Commercial lenders will look at a district hospital and offer three years for an asset that pays back over seven.
That mismatch is precisely what concessional debt and guarantees exist to fix. A guarantee costs a fee and no equity. Concessional debt costs interest and no equity. For a healthcare business building physical infrastructure in places commercial lenders avoid, getting this right is worth more than any amount of narrative work.
Split the requirement before you raise.
Equipment and fit-out is a debt question. Proving a new model in a district nobody has served is a grant question. Expansion once the model works is an equity question. Most healthcare raises I see fund all three from one instrument.
Where to start
If you're running a healthcare business that serves people the system generally skips, three things are worth doing before you approach anyone.
- Work out honestly whether commercial capital would fund this. If it would, stop here and go there.
- Go into your own records and assemble what you already hold: geography, what people paid, who was there for the first time, what happened next. Almost all of it exists.
- Split your capital requirement by what the money is doing, rather than by what round you think you're raising.
Healthcare is the warmest sector in this lane. It's also the one where the wrong instrument costs the most, because the assets are heavy and the payback is slow.
If you want to know whether your healthcare business clears the four gates, and which instruments fit the assets you're funding, start with the Capital Roadmap Diagnostic.
How useful was this article?
One tap. It tells us what to write more of.
The next one
Get what we publish next, by email.
Working notes on raising, borrowing, protecting, growing and structuring capital in India. One email a week at most, and you can leave any time.
We use your address only to send this. See our privacy policy.
We store your address to send you these emails and nothing else. See our privacy policy.
Related reading
